Key result
LV ECV by T1 mapping predicts ~26% higher risk of cardiac death, stroke, or HF.
Why the study?
It was unknown whether left ventricular fibrosis quantified by T1 mapping could serve as a biomarker to predict outcomes in patients with atrial fibrillation and heart failure.
Does left ventricular fibrosis assessed by T1 mapping predict composite adverse outcomes in patients with atrial fibrillation and heart failure?
Population
108 patients with AF and HF
Comparison
LV fibrosis quantified by T1 mapping
Design
Observational cohort study
Follow-up
Median 23 months
Authors
Loading...
LV ECV by T1 mapping was associated with worse outcomes in AF-HF; leaves open its added value for risk stratification beyond clinical scores.
Observational (n=108)
Single-blind
No
Does left ventricular fibrosis assessed by T1 mapping predict composite adverse outcomes in patients with atrial fibrillation and heart failure?
Hazard Ratio: 1.258 (95% CI 1.14–1.388)
p-value: p=<0.001
Left ventricular fibrosis measured by T1 mapping indices significantly predicts composite adverse outcomes and subsequent heart failure in patients with atrial fibrillation and heart failure.
Zhao et al. (2019) conducted an observational in Atrial Fibrillation and Heart Failure (n=108). Left ventricular extracellular volume fraction (LV ECV) vs. Per 1% increase was evaluated on Composite adverse outcome of cardiac death, subsequent HF or stroke (HR 1.258, 95% CI 1.140-1.388, p=<0.001). Left ventricular extracellular volume fraction assessed by T1 mapping independently predicted the composite adverse outcome of cardiac death, stroke, or heart failure readmission (HR 1.258).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: